Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Inclusion Criteria:

• Subjects of Chinese descent with full Chinese parentage.

• Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0.

• Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than orequal to 450 despite treatment with oral corticosteroids and/or immunosuppressants.

• Subject has a negative Tuberculosis (TB) Screening Assessment.

• Subject has elevated high sensitivity C-reactive protein (hs-CRP) during the ScreeningPeriod.

Exclusion Criteria:

• Subject with ulcerative colitis or indeterminate colitis.

• Subject who has had a surgical bowel resection within the past 6 months or who isplanning any resection at any time point in the future.

• Subject with an ostomy or ileoanal pouch.

• Subject who has short bowel syndrome.

• Subject with symptomatic known obstructive strictures.

• Subject with an internal or external fistula (with the exception of an anal fistulawithout abscess).

• Active, or chronic or recurring infections, or active tuberculosis.